Does Idera Pharmaceuticals Inc (IDRA) Have Any Gas After Today’s Big Increase?

September 17, 2017 - By Marie Mckinney

Investors sentiment increased to 3.31 in 2016 Q4. Its up 1.26, from 2.05 in 2016Q3. It increased, as 9 investors sold Idera Pharmaceuticals Inc shares while 7 reduced holdings. 14 funds opened positions while 39 raised stakes. 96.26 million shares or 180.02% more from 34.38 million shares in 2016Q3 were reported.
Wells Fargo And Mn has invested 0% in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Geode Management Ltd Liability Corp accumulated 0% or 867,504 shares. Mycio Wealth Ptnrs Ltd Com holds 0.05% or 246,527 shares in its portfolio. Commercial Bank Of New York Mellon holds 0% of its portfolio in Idera Pharmaceuticals Inc (NASDAQ:IDRA) for 354,520 shares. Blackrock Fund has 3.29M shares for 0% of their portfolio. Tci Wealth Advsrs Inc owns 3,600 shares. Schwab Charles Investment Mgmt Incorporated invested in 0% or 166,529 shares. Commonwealth Equity holds 34,600 shares. Leavell Management Inc holds 81,271 shares or 0.02% of its portfolio. California State Teachers Retirement Systems has invested 0% in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Art Advsrs Lc accumulated 0.01% or 60,935 shares. Kcg Holding Inc reported 84,019 shares. Moreover, Nationwide Fund Advsr has 0% invested in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Bnp Paribas Arbitrage reported 5,956 shares. Barclays Public Ltd Com holds 0% of its portfolio in Idera Pharmaceuticals Inc (NASDAQ:IDRA) for 1,953 shares.

Since May 1, 2017, it had 0 insider buys, and 1 insider sale for $1.02 million activity. 450,815 shares valued at $1.02M were sold by Pillar Invest Corp on Monday, May 1.

The stock of Idera Pharmaceuticals Inc (NASDAQ:IDRA) is a huge mover today! The stock increased 5.50% or $0.11 on September 15, reaching $2.11. About 1.77M shares traded or 77.17% up from the average. Idera Pharmaceuticals Inc (NASDAQ:IDRA) has risen 21.13% since September 17, 2016 and is uptrending. It has outperformed by 4.43% the S&P500.
The move comes after 5 months positive chart setup for the $315.72M company. It was reported on Sep, 17 by Barchart.com. We have $2.28 PT which if reached, will make NASDAQ:IDRA worth $25.26 million more.

Analysts expect Idera Pharmaceuticals Inc (NASDAQ:IDRA) to report $-0.12 EPS on October, 27.They anticipate $0.02 EPS change or 20.00 % from last quarter’s $-0.1 EPS. After having $-0.14 EPS previously, Idera Pharmaceuticals Inc’s analysts see -14.29 % EPS growth.

Idera Pharmaceuticals Inc (NASDAQ:IDRA) Ratings Coverage

Among 3 analysts covering Idera Pharma (NASDAQ:IDRA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Idera Pharma had 4 analyst reports since January 6, 2016 according to SRatingsIntel. Wedbush maintained Idera Pharmaceuticals Inc (NASDAQ:IDRA) on Wednesday, February 1 with “Outperform” rating. Piper Jaffray maintained Idera Pharmaceuticals Inc (NASDAQ:IDRA) on Monday, September 11 with “Buy” rating. Wedbush initiated Idera Pharmaceuticals Inc (NASDAQ:IDRA) on Wednesday, January 6 with “Outperform” rating.

More important recent Idera Pharmaceuticals Inc (NASDAQ:IDRA) news were published by: Nasdaq.com which released: “Idera Pharmaceuticals (IDRA) Jumps: Stock Rises 14.4%” on September 12, 2017, also Seekingalpha.com published article titled: “Idera Pharmaceuticals: This ESMO Winner Is A Buy”, Globenewswire.com published: “Idera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment in …” on September 08, 2017. More interesting news about Idera Pharmaceuticals Inc (NASDAQ:IDRA) was released by: Fool.com and their article: “Here’s Why Idera Pharmaceuticals, Inc. Is Surging Today” with publication date: September 11, 2017.

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The company has market cap of $315.72 million. The Firm utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor targeting technology and third-generation antisense (3GA) technology. It currently has negative earnings. Using TLR technology, the Company creates synthetic oligonucleotide drug candidates to act by modulating the activity of specific TLRs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.